A PCORI-funded study looked at whether ketamine given through an intravenous, or IV, line worked as well as electroconvulsive therapy, or ECT, to relieve depression that has not improved with medicine alone.


A young adult Hispanic male sits on a couch in a mental health counselors office, opposite an unidentified adult female, having a conversation.

Findings

Icon for findings

A PCORI-funded study found that IV ketamine worked at least as well as ECT to relieve symptoms of TRD after three weeks of treatment.

The study also found that:

  • Both treatments improved people’s quality of life.
  • At the end of three weeks of treatment, people who received ECT had more memory loss than people who received ketamine. Within one month after completing treatment, memory loss returned to similar levels as those seen in the IV ketamine group.
  • People reported side effects during the three weeks of treatment. Among patients who received either ECT or IV ketamine, the most common side effects included headaches, muscle pain, and stomach problems. Patients who received ECT also reported muscle weakness. Patients receiving IV ketamine also experienced high blood pressure.
  • More people who received ECT had muscle pain or weakness after each treatment than people who received IV ketamine.

Depression is a health problem that causes people to feel sad, hopeless, or empty. For many, these feelings show up most days and last more than two weeks. Medicines, such as antidepressants, are often used to treat depression. Treatment-resistant depression, or TRD, occurs when someone has tried at least two medicines, but their symptoms don’t improve.

It can take 6–12 weeks to learn whether another medicine might work to relieve symptoms for a patient with TRD. But some patients need a faster treatment option to relieve their TRD symptoms.

This study looked at two options to help patients with TRD get rapid relief of symptoms:

➤ ECT has been used for decades to treat TRD symptoms for some patients. During ECT, a small amount of electrical current passes through the brain via an electrode on one or both sides of the patient’s head. The current causes a seizure that affects chemicals in the brain. During ECT, doctors give patients medicine to bring on a sleep-like state.

➤ Ketamine is a newer treatment for TRD. Ketamine affects chemicals in the brain and can help people develop more positive thoughts. Ketamine can be taken as a nose spray or through an IV; in this study, patients received ketamine through an IV. Patients remain awake during treatment.

The research team wanted to learn whether IV ketamine worked at least as well as ECT for improving the symptoms of TRD. The team also looked at the side effects of ECT and ketamine during three weeks of treatment and at whether these treatments changed patients’ memory and quality of life.

The US Food and Drug Administration, or FDA, has approved ketamine given as a nose spray for TRD. But it has not approved IV ketamine for this purpose. Health insurance may not cover the cost of IV ketamine. The study didn’t look at ketamine given as a nose spray.

Other Important Information About Treating TRD

ECT and IV ketamine for TRD are both prescribed by a psychiatrist. Your psychiatrist will talk with you about your personal and medical history to help you decide the best treatment for you.

If your psychiatrist refers you to treatment with ketamine, it is important to know where you can safely get this treatment. You should only get IV ketamine treatment from a clinic with trained staff who can watch how you respond.

What Should I Ask My Clinician?

If your psychiatrist refers you for treatment with IV ketamine or ECT, questions to ask your psychiatrist include:

➤ When should I expect to see my symptoms improve if I am treated with ECT or IV ketamine?

➤ Do I have to stay at a hospital to get ECT or IV ketamine?

➤ What side effects can I expect from ECT or IV ketamine?

➤ Would I continue to take my other depression medicines before and after I receive ECT or IV ketamine?

➤ Would you be providing the ECT or IV ketamine treatment? If not, where would you recommend that I get the treatment?

About the Study

Icon for about the study

In this study, the research team assigned 403 people with TRD by chance to receive either ECT or IV ketamine for three weeks. All people in the study were referred for ECT by their doctor. The study didn’t include people with TRD who had symptoms of psychosis. The average age was 46. All received care from one of five clinics across five states.

People in the IV ketamine group received treatment for 40 minutes two times a week. People in the ECT group had treatment up to three times a week. All treatments took place in a hospital. Most patients did not stay overnight and went home the same day after each treatment. Patients could continue talk therapy and other medicines while in the study.

Read more about this study at www.pcori.org/Anand545

Download this Evidence Update

Logos for PCORI and the Anxiety and Depression Association of America (ADAA) and NAMI (the National Alliance on Mental Illness) -- partner organizations for the Evidence Updates on Comparing Two Options for Treatment-Resistant Depression

SOURCES

© 2011–2026 Patient-Centered Outcomes Research Institute. “Comparing Ketamine Versus Electroconvulsive Therapy for Patients with Treatment-Resistant Depression -- The ELEKT-D Study.” Updated February 25, 2026. https://www.pcori.org/Anand545

Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388(25):2315-2325. https://doi.org/10.1056/NEJMoa2302399

The information in this publication is not intended to be a substitute for professional medical advice. This update summarizes findings from a PCORI research award to Cleveland Clinic Foundation.


Last reviewed: July 13, 2026

Stay Connected

Get weekly updates about opportunities to apply for funding, newly funded research and engagement projects, results of PCORI-funded research, webinars and other news.